Radiation plus docetaxel and cisplatin in locally advanced pancreatic carcinoma: A non-comparative randomized phase II trial
Michel Ducreux(Université Paris-Saclay), F. Viret, F. Mornex(Hôpital Lyon Sud), Antoine Adenis(Inserm), Jaafar Bennouna(Hôpital Foch), Valérie Boige(Inserm), Jean‐Pierre Pignon(Inserm), D. Peiffert(Institut de Cancérologie de Lorraine), Béata Juzyna(UniCancer Group), Marc Giovannini(Institut Paoli-Calmettes), Moncef Abbas(Institut Gustave Roussy), Thierry Conroy(Institut de Cancérologie de Lorraine), Charlotte Baey(Institut Gustave Roussy), C. Llacer(Inserm), P. Cellier(Institut de Cancérologie de l'Ouest)
Cited by 8
Related Papers
The consensus molecular subtypes of colorectal cancer
|Nature Medicine|2015|5.3k
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations
|Journal of Clinical Oncology|2013|3.2k
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
|New England Journal of Medicine|2018|2.9k
Perioperative Chemotherapy Compared With Surgery Alone for Resectable Gastroesophageal Adenocarcinoma: An FNCLCC and FFCD Multicenter Phase III Trial
|Journal of Clinical Oncology|2011|2.1k
Meta-Analysis of Concomitant Versus Sequential Radiochemotherapy in Locally Advanced Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2010|1.9k